AbbVie to acquire Apogee Therapeutics for $10.9B
Apogee Therapeutics agreed to be acquired by AbbVie for approximately $10.9 billion while also reporting Q2 2026 financial results and positive Phase 2 data for its atopic dermatitis candidate, which may bolster the acquisition price.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day